Search academic texts

Information × Registration Number 0209U006186, 0104U010832 , R & D reports Title Investigation of biologic effects of recombinant interferon alpha drugs and sygnal transduction inhibitor imatinib in conditions of modern therapy of chronic myeloid leukemia. popup.stage_title Head Masliak Zvenyslava Volodymyrivna, Registration Date 17-02-2009 Organization State Institution "Institute of Blood Pathology and Transfusion Medicine AMS Ukraine" popup.description2 Subject of investigation - blood and bone marrow cells of patients with chronic myeloid leukemia (CML) at the different time points and during remission in 89 patients of age from 18 to 65 years. Tests were performed before imatinib (IM) treatment initiation and after 1,5; 3; 6; 12; 18 and 24 months of treatment. Methods: cytological, cytochemical, cytogenetical, immunological, statistical. Determination of the serum levels of vascular endothelial growth factor (VEGF), tumor necrosis factor alfa (TNF) and the TNF soluble receptors of type I and type II was performed. The optimal treatment regimen for the 1st line treatment of CML is administration of IM. Comparison of the serum levels of cytokines before IM initiation with the results of clinical-hematological and cytogenetic investigations confirmed that the increased level of VEGF reflects adequately the activity of the leukemic process. Similar results were obtained concerning TNF-alfa as well. As the patients were receiving IM treatment the serum level of VEGF started to decrease significantly already after 1,5 months of treatment. At this very time point no quantitative changes were observed in the bone marrow karyotype yet. Determination of the serum levels of VEGF and TNF-alfa at different time points may be recommended as an independent prognostic factor of IM treatment response in CML. Product Description popup.authors popup.nrat_date 2020-04-02 Close